Inhaled Therapies for Pulmonary Hypertension

References

1. 1.↵
   1. Simonneau G,
   2. Gatzoulis MA,
   3. Adatia I,
   4. Celermajer D,
   5. Denton C,
   6. Ghofrani A,
   7. et al

   . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D34-D41.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Moncada S,
   2. Gryglewski R,
   3. Bunting S,
   4. Vane JR

   . An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263(5579):663-665.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Moncada S,
   2. Vane JR

   . The role of prostacyclin in vascular tissue. Fed Proc 1979;38(1):66-71.

   OpenUrlPubMedWeb of Science
4. 4.↵
   1. Lin H,
   2. Lee JL,
   3. Hou HH,
   4. Chung CP,
   5. Hsu SP,
   6. Juan SH

   . Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J Cell Physiol 2008;214(2):434-441.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Barst RJ,
   2. Rubin LJ,
   3. Long WA,
   4. McGoon MD,
   5. Rich S,
   6. Badesch DB,
   7. et al

   . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334(5):296-301.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. De Wet CJ,
   2. Affleck DG,
   3. Jacobsohn E,
   4. Avidan MS,
   5. Tymkew H,
   6. Hill LL,
   7. et al

   . Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 2004;127(4):1058-1067.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Preston IR,
   2. Sagliani KD,
   3. Roberts KE,
   4. Shah AM,
   5. Desouza SA,
   6. Howard W,
   7. et al

   . Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension. Pulm Circ 2013;3(1):68-73.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Olschewski H,
   2. Rohde B,
   3. Behr J,
   4. Ewert R,
   5. Gessler T,
   6. Ghofrani HA,
   7. Schmehl T

   . Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003;124(4):1294-304.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Olschewski H,
   2. Simonneau G,
   3. Galiè N,
   4. Higenbottam T,
   5. Naeije R,
   6. Rubin LJ,
   7. et al

   . Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322-329.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Olschewski H,
    2. Ghofrani HA,
    3. Walmrath D,
    4. Schermuly R,
    5. Temmesfeld-Wollbruck B,
    6. Grimminger F,
    7. Seeger W

    . Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999;160(2):600-607.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Ivy DD,
    2. Doran AK,
    3. Smith KJ,
    4. Mallory GB Jr.,
    5. Beghetti M,
    6. Barst RJ,
    7. et al

    . Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008;51(2):161-169.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Kramm T,
    2. Eberle B,
    3. Guth S,
    4. Mayer E

    . Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardiothorac Surg 2005;28(6):882-888.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Voswinckel R,
    2. Enke B,
    3. Reichenberger F,
    4. Kohstall M,
    5. Kreckel A,
    6. Krick S,
    7. et al

    . Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006;48(8):1672-1681.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. McLaughlin VV,
    2. Benza RL,
    3. Rubin LJ,
    4. Channick RN,
    5. Voswinckel R,
    6. Tapson VF,
    7. et al

    . Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55(18):1915-1922.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. de Jesus Perez VA,
    2. Rosenzweig E,
    3. Rubin LJ,
    4. Poch D,
    5. Bajwa A,
    6. Park M,
    7. et al

    . Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol 2012;110(10):1546-1550.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Preston IR,
    2. Feldman J,
    3. White J,
    4. Franco V,
    5. Ishizawar D,
    6. Burger C,
    7. et al

    . Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension. Pulm Circ 2014;4(3):456-461.

    OpenUrlPubMed
17. 17.↵
    1. Moncada S,
    2. Higgs EA

    . Nitric oxide and the vascular endothelium. Handb Exp Pharmacol 2006;(176 Pt 1):213-254.
18. 18.↵
    1. Guzik TJ,
    2. Korbut R,
    3. Adamek-Guzik T

    . Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003;54(4):469-487.

    OpenUrlPubMedWeb of Science
19. 19.↵
    1. Sitbon O,
    2. Humbert M,
    3. Jaïs X,
    4. Ioos V,
    5. Hamid AM,
    6. Provencher S,
    7. et al

    . Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111(23):3105-3111.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Malhotra R,
    2. Hess D,
    3. Lewis GD,
    4. Bloch KD,
    5. Waxman AB,
    6. Semigran MJ

    . Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension. Pulm Circ 2011;1(2):250-258.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Bhorade S,
    2. Christenson J,
    3. O'Connor M,
    4. Lavoie A,
    5. Pohlman A,
    6. Hall JB

    . Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med 1999;159(2):571-579.

    OpenUrlPubMedWeb of Science
22. 22.↵
    1. Christenson J,
    2. Lavoie A,
    3. O'Connor M,
    4. Bhorade S,
    5. Pohlman A,
    6. Hall JB

    . The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide. Am J Respir Crit Care Med 2000;161(5):1443-1449.

    OpenUrlPubMedWeb of Science
23. 23.↵
    1. Atz AM,
    2. Wessel DL

    . Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999;91(1):307-310.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.↵
    1. Channick RN,
    2. Newhart JW,
    3. Johnson FW,
    4. Williams PJ,
    5. Auger WR,
    6. Fedullo PF,
    7. Moser KM

    . Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 1996;109(6):1545-1549.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Preston IR,
    2. Klinger JR,
    3. Landzberg MJ,
    4. Houtchens J,
    5. Nelson D,
    6. Hill NS

    . Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001;120(3):866-872.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Ichinose F,
    2. Erana-Garcia J,
    3. Hromi J,
    4. Raveh Y,
    5. Jones R,
    6. Krim L,
    7. et al

    . Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001;29(5):1000-1005.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Said SI,
    2. Mutt V

    . Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature 1970;225(5235):863-864.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Petkov V,
    2. Mosgoeller W,
    3. Ziesche R,
    4. Raderer M,
    5. Stiebellehner L,
    6. Vonbank K,
    7. et al

    . Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111(9):1339-1346.

    OpenUrlCrossRefPubMedWeb of Science
29. 29.↵
    1. Galie N,
    2. Boonstra A,
    3. Ewert R,
    4. Gomez-Sanchez MA,
    5. Barbera JA,
    6. Torbicki A,
    7. et al

    . Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH) (abstract). Am J Respir Crit Care Med 2010;181:A2516.

    OpenUrl
30. 30.↵
    1. Loirand G,
    2. Guérin P,
    3. Pacaud P

    . Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006;98(3):322-334.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Nagaoka T,
    2. Fagan KA,
    3. Gebb SA,
    4. Morris KG,
    5. Suzuki T,
    6. Shimokawa H,
    7. et al

    . Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005;171(5):494-499.

    OpenUrlPubMedWeb of Science
32. 32.↵
    1. Hoeper MM,
    2. Barst RJ,
    3. Bourge RC,
    4. Feldman J,
    5. Frost AE,
    6. Galié N,
    7. et al

    . Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013;127(10):1128-1138.

    OpenUrlAbstract/FREE Full Text